raltegravir + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
HIV Infection
Conditions
HIV Infection, Inflammation, Cardiovascular Disease, HIV Infections
Trial Timeline
Jan 1, 2009 → Feb 1, 2014
NCT ID
NCT00843713About raltegravir + Placebo
raltegravir + Placebo is a approved stage product being developed by Merck for HIV Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00843713. Target conditions include HIV Infection, Inflammation, Cardiovascular Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00843713 | Approved | Completed |
| NCT00562510 | Phase 3 | Terminated |
| NCT00631449 | Approved | Completed |
Competing Products
20 competing products in HIV Infection